<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">
      <span class="gem-c-organisation-logo__name">Medicines &amp; Healthcare products<br>Regulatory Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Open consultation
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Annex B - MHRA Statutory fee proposals
  </h1>
</div>
  <p class="publication-header__last-changed">Published 31 August 2022</p>

  </header>






<div class="sidebar-with-body">
  <div class="govuk-grid-row">
      <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
          <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#table-1--10-indexation-increase-in-line-with-increased-pay-costs" data-track-options="{&quot;dimension29&quot;:&quot;Table 1 – 10% Indexation increase in line with increased pay costs&quot;}" href="#table-1--10-indexation-increase-in-line-with-increased-pay-costs">Table 1 – 10% Indexation increase in line with increased pay costs</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#table-2--fees-that-increase-above-indexation-to-achieve-cost-based-recovery" data-track-options="{&quot;dimension29&quot;:&quot;Table 2 – Fees that increase above indexation to achieve cost-based recovery&quot;}" href="#table-2--fees-that-increase-above-indexation-to-achieve-cost-based-recovery">Table 2 – Fees that increase above indexation to achieve cost-based recovery</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#table-3--new-fees" data-track-options="{&quot;dimension29&quot;:&quot;Table 3 – New Fees&quot;}" href="#table-3--new-fees">Table 3 – New Fees</a>

        </li>
    </ol>
</nav>

        
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-ga4="{&quot;event_name&quot;:&quot;print_page&quot;,&quot;type&quot;:&quot;Print this page&quot;,&quot;index&quot;:1,&quot;index_total&quot;:1,&quot;section&quot;:&quot;Contents&quot;}" data-module="ga4-event-tracker print-link">Print this page</button>
</div>
      </div>

    <div class="print-wrapper">
      <div class="print-meta-data">
        <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/consultations/consultation-on-proposals-for-changes-to-the-medicines-and-healthcare-products-regulatory-agencys-statutory-fees/annex-b-mhra-statutory-fee-proposals
</p>


      </div>
    </div>

    <div class="main-content-container">
      <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
        <div class="govspeak">
<p>Proposed statutory fees from 1 April 2023</p>

<h2>Table 1 – 10% Indexation increase in line with increased pay costs</h2>

<table>
  <thead>
    <tr>
      <th scope="col">Level 1    Descriptor</th>
      <th scope="col">Level 2    Descriptor</th>
      <th scope="col">Level 3    Descriptor</th>
      <th scope="col">Fee Name</th>
      <th scope="col">Current Fee (£)</th>
      <th scope="col">Proposed Fee (£)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   manufacturers</td>
      <td>New applications</td>
      <td>New application for registration as a   manufacturer of active substances</td>
      <td>5,006</td>
      <td>5,507</td>
    </tr>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   importer or distributor</td>
      <td>New applications</td>
      <td>New application for registration as an   importer or distributor of active substances</td>
      <td>3,157</td>
      <td>3,473</td>
    </tr>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   importer or distributor</td>
      <td>New applications</td>
      <td>Additional fee if the risk assessment of   the initial application triggers an inspection</td>
      <td>582</td>
      <td>640</td>
    </tr>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   importer or distributor</td>
      <td>Variations</td>
      <td>Notification of changes (variation)</td>
      <td>257</td>
      <td>283</td>
    </tr>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   importer or distributor</td>
      <td>Annual compliance report</td>
      <td>Assessment of the annual compliance report</td>
      <td>257</td>
      <td>283</td>
    </tr>
    <tr>
      <td>1. Active pharmaceutical ingredients   manufacturers and importers registration: fees</td>
      <td>Fees for registration of active substance   importer or distributor</td>
      <td>Annual compliance report</td>
      <td>Annual compliance report where a variation   is required</td>
      <td>514</td>
      <td>565</td>
    </tr>
    <tr>
      <td>2. Active substance importers or   distributors: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application for registration</td>
      <td>1,803</td>
      <td>1,983</td>
    </tr>
    <tr>
      <td>2. Active substance importers or   distributors: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Assessment of initial application: active   substance importer / distributor</td>
      <td>1,354</td>
      <td>1,489</td>
    </tr>
    <tr>
      <td>2. Active substance importers or   distributors: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Additional fee for the first day of   inspection if triggered following risk-assessment of the application</td>
      <td>582</td>
      <td>640</td>
    </tr>
    <tr>
      <td>2. Active substance importers or   distributors: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Persons appointed appeals procedure fee</td>
      <td>10,000</td>
      <td>11,000</td>
    </tr>
    <tr>
      <td>3. Active substance manufacturers:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application for registration</td>
      <td>3,143</td>
      <td>3,457</td>
    </tr>
    <tr>
      <td>3. Active substance manufacturers:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Assessment of Initial Application</td>
      <td>1,863</td>
      <td>2,049</td>
    </tr>
    <tr>
      <td>3. Active substance manufacturers:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Additional fee for the first day of an   inspection if triggered following risk-assessment of the application</td>
      <td>792</td>
      <td>871</td>
    </tr>
    <tr>
      <td>4. Blood banks: application fees for a   Review Panel hearing</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Fee</td>
      <td>10,000</td>
      <td>11,000</td>
    </tr>
    <tr>
      <td>5. Blood banks and other blood   establishments: fees</td>
      <td>Blood Establishments</td>
      <td>New Applications</td>
      <td>Standard application</td>
      <td>3,074</td>
      <td>3,381</td>
    </tr>
    <tr>
      <td>5. Blood banks and other blood   establishments: fees</td>
      <td>Blood Establishments</td>
      <td>Variations</td>
      <td>Standard variation</td>
      <td>518</td>
      <td>570</td>
    </tr>
    <tr>
      <td>5. Blood banks and other blood   establishments: fees</td>
      <td>Blood Establishments</td>
      <td>Periodic Fee</td>
      <td>Annual fee</td>
      <td>463</td>
      <td>509</td>
    </tr>
    <tr>
      <td>5. Blood banks and other blood   establishments: fees</td>
      <td>Hospital Blood Banks and facilities</td>
      <td>Compliance</td>
      <td>Annual fee</td>
      <td>683</td>
      <td>751</td>
    </tr>
    <tr>
      <td>7. Broker registration fees</td>
      <td>Broker registration fees</td>
      <td>New Applications</td>
      <td>New application for registration as a   broker</td>
      <td>3,157</td>
      <td>3,473</td>
    </tr>
    <tr>
      <td>7. Broker registration fees</td>
      <td>Broker registration fees</td>
      <td>New Applications</td>
      <td>Additional fee if the risk assessment of   the initial application triggers an inspection</td>
      <td>582</td>
      <td>640</td>
    </tr>
    <tr>
      <td>7. Broker registration fees</td>
      <td>Broker registration fees</td>
      <td>Annual Compliance Report</td>
      <td>Annual Compliance where a variation is   required</td>
      <td>514</td>
      <td>565</td>
    </tr>
    <tr>
      <td>8. Clinical trials: application fees</td>
      <td>&nbsp;</td>
      <td>Applications with an IMP dossier</td>
      <td>Higher fee (Phase 1, Full and Simplified   IMPD)</td>
      <td>3,060</td>
      <td>3,366</td>
    </tr>
    <tr>
      <td>8. Clinical trials: application fees</td>
      <td>&nbsp;</td>
      <td>Applications without an IMP dossier</td>
      <td>Lower fee (Phase IV, Cross referral,   Additional protocol)</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>8. Clinical trials: application fees</td>
      <td>&nbsp;</td>
      <td>CT variations/amendments</td>
      <td>&nbsp;</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Initial Consultation for a Device which   incorporates one or more known medicinal substances from an approved   manufacturer of that substance</td>
      <td>4,136</td>
      <td>4,550</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Further consultation of a Device which   incorporates one or more known medicinal substances from an approved manufacturer   of that substance</td>
      <td>818</td>
      <td>900</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Initial Consultation for a Device which   incorporates one or more known medicinal substances from a new source</td>
      <td>9,640</td>
      <td>10,604</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Further consultation of a Device which   incorporates one or more known medicinal substances from a new source</td>
      <td>2,228</td>
      <td>2,451</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Initial consultation for a Device which   incorporates a new active substance</td>
      <td>42,296</td>
      <td>46,526</td>
    </tr>
    <tr>
      <td>10. Drug-device combination products:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Further consultation of a Device which   incorporates a new active substance</td>
      <td>10,501</td>
      <td>11,551</td>
    </tr>
    <tr>
      <td>12. Homeopathic National Rules Scheme:   fees for inspections</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>GDP (wholesale dealers including   homeopathic wholesalers)</td>
      <td>1,328</td>
      <td>1,461</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Major Orphan (reduced in exceptional circumstances)</td>
      <td>29,732</td>
      <td>32,705</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition procedure for   sale or supply in Northern Ireland and any subsequent Unfettered access route   for UKMA(GB)</td>
      <td>62,421</td>
      <td>68,663</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>European reference product application for   sale or supply in Northern Ireland</td>
      <td>62,421</td>
      <td>68,663</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Decentralised procedure for sale or supply   in Northern Ireland and any subsequent Unfettered access route for UKMA(GB)</td>
      <td>62,421</td>
      <td>68,663</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Major: (Previously granted by EU) -   unfettered access route to GB</td>
      <td>18,437</td>
      <td>20,281</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Major: (Previously granted by EEA) – application   for GB or UK, excluding GB unfettered access route (MRDC reliance procedure)</td>
      <td>62,421</td>
      <td>68,663</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>Major: (Previously granted by EU) -   automatic recognition application (EC Decision reliance procedure)</td>
      <td>18,437</td>
      <td>20,281</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Major</td>
      <td>&nbsp;</td>
      <td>National fee (any other case including   hybrid applications)</td>
      <td>92,753</td>
      <td>102,028</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition procedure for   sale or supply in Northern Ireland and any subsequent Unfettered access route   for UKMA(GB)</td>
      <td>17,330</td>
      <td>19,063</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>European reference product application for   sale or supply in Northern Ireland</td>
      <td>17,330</td>
      <td>19,063</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>Decentralised procedure for the sale or   supply in Northern Ireland and any subsequent Unfettered access route for   UKMA(GB)</td>
      <td>17,330</td>
      <td>19,063</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>Complex: (Previously granted by EU) -   unfettered access route to GB</td>
      <td>10,443</td>
      <td>11,487</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>Complex: (Previously granted by EEA) –   application for GB or UK, excluding GB unfettered access route (MRDC reliance   procedure)</td>
      <td>17,330</td>
      <td>19,063</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>Complex: (Previously granted by EU) -   automatic recognition application (EC Decision reliance procedure)</td>
      <td>10,443</td>
      <td>11,487</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged complex</td>
      <td>&nbsp;</td>
      <td>National fee (any other case including   hybrid applications)</td>
      <td>25,643</td>
      <td>28,207</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition procedure for   sale or supply in Northern Ireland and any subsequent Unfettered access route   for a UKMA(GB)</td>
      <td>6,350</td>
      <td>6,985</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>European reference product application for   sale or supply in Northern Ireland</td>
      <td>6,350</td>
      <td>6,985</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>Decentralised procedure for sale or supply   in Northern Ireland and any subsequent Unfettered access route for UKMA(GB)</td>
      <td>6,350</td>
      <td>6,985</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>Standard: (Previously granted by EU) -   unfettered access route to GB</td>
      <td>5,783</td>
      <td>6,361</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>Standard: (Previously granted by EEA) –   application for GB or UK, excluding GB unfettered access route (MRDC reliance   procedure)</td>
      <td>6,350</td>
      <td>6,985</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>Standard: (Previously granted by EU) -   automatic recognition application (EC Decision reliance procedure)</td>
      <td>5,783</td>
      <td>6,361</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged standard</td>
      <td>&nbsp;</td>
      <td>National fee (all other cases)</td>
      <td>9,402</td>
      <td>10,342</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition procedure for   sale or supply in Northern Ireland and any subsequent Unfettered access route   for UKMA(GB)</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>Decentralised procedure for sale or supply   in Northern Ireland and any subsequent Unfettered access route for UKMA(GB)</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>Simple: (Previously granted by EU) -   unfettered access route to GB</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>Simple: (Previously granted by EEA) –   application for GB or UK, excluding GB unfettered access route (MRDC reliance   procedure)</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing authorisations   (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>Simple: (Previously granted by EU) -   automatic recognition application (EC Decision reliance procedure)</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Abridged simple</td>
      <td>&nbsp;</td>
      <td>National fee (all other cases)</td>
      <td>2,564</td>
      <td>2,820</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Extension application group</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition (UK CMS)</td>
      <td>17,330</td>
      <td>19,063</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Extension application group bulk</td>
      <td>&nbsp;</td>
      <td>Decentralised procedure where the UK is CMS</td>
      <td>9,078</td>
      <td>9,986</td>
    </tr>
    <tr>
      <td>14. Licence applications: marketing   authorisations (including extension applications) fees</td>
      <td>Extension application group bulk</td>
      <td>&nbsp;</td>
      <td>Incoming mutual recognition (UK CMS)</td>
      <td>6,350</td>
      <td>6,985</td>
    </tr>
    <tr>
      <td>15. Licence applications:   manufacturers licence (including THMPD and homeopathic medicinal products)   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Standard</td>
      <td>3,143</td>
      <td>3,457</td>
    </tr>
    <tr>
      <td>15. Licence applications:   manufacturers licence (including THMPD and homeopathic medicinal products)   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Non-orthodox practitioner (NOP)</td>
      <td>183</td>
      <td>201</td>
    </tr>
    <tr>
      <td>15. Licence applications:   manufacturers licence (including THMPD and homeopathic medicinal products)   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Change of ownership</td>
      <td>344</td>
      <td>378</td>
    </tr>
    <tr>
      <td>16. Licence applications: parallel   imports fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Complex application</td>
      <td>18,180</td>
      <td>19,998</td>
    </tr>
    <tr>
      <td>16. Licence applications: parallel   imports fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Simple application</td>
      <td>1,792</td>
      <td>1,971</td>
    </tr>
    <tr>
      <td>16. Licence applications: parallel   imports fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Change of ownership (including THMPD   registrations)</td>
      <td>442</td>
      <td>486</td>
    </tr>
    <tr>
      <td>17. Licence applications: Phase 1   Accreditation Scheme fees</td>
      <td>&nbsp;</td>
      <td>Phase I Accreditation Scheme</td>
      <td>Accreditation of Phase 1 units</td>
      <td>117</td>
      <td>129</td>
    </tr>
    <tr>
      <td>17. Licence applications: Phase 1   Accreditation Scheme fees</td>
      <td>&nbsp;</td>
      <td>Phase I Accreditation Scheme</td>
      <td>Certificate of accreditation</td>
      <td>62</td>
      <td>68</td>
    </tr>
    <tr>
      <td>18. Medicines export certificates:   fees</td>
      <td>&nbsp;</td>
      <td>Urgent request: two working days per set</td>
      <td>Original and two copies</td>
      <td>152</td>
      <td>167</td>
    </tr>
    <tr>
      <td>18. Medicines export certificates:   fees</td>
      <td>&nbsp;</td>
      <td>Standard request: ten working days per set</td>
      <td>Original and two copies</td>
      <td>68</td>
      <td>75</td>
    </tr>
    <tr>
      <td>18. Medicines export certificates:   fees</td>
      <td>&nbsp;</td>
      <td>Standard request: ten working days per set</td>
      <td>Each additional copy</td>
      <td>34</td>
      <td>37</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>New active substance (1)</td>
      <td>9,710</td>
      <td>10,681</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Derivatives with a different route of administration   (1) or complex abridged (2)</td>
      <td>9,710</td>
      <td>10,681</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Other derivatives (1)</td>
      <td>6,554</td>
      <td>7,209</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>Prescription only medicine</td>
      <td>Standard fee</td>
      <td>2,428</td>
      <td>2,671</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>Prescription only medicine</td>
      <td>Reduced rate fee</td>
      <td>1,211</td>
      <td>1,332</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>Prescription only medicine</td>
      <td>‘Maintenance’ fee</td>
      <td>307</td>
      <td>338</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>Prescription only medicine</td>
      <td>All others (P, GSL, PLPI and None)</td>
      <td>307</td>
      <td>338</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Herbal</td>
      <td>76</td>
      <td>84</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Homeopathic and Anthroposophic PLRs (per   PLR)</td>
      <td>76</td>
      <td>84</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>National Rules Homeopathic Authorisation</td>
      <td>76</td>
      <td>84</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Manufacturer’s licence</td>
      <td>468</td>
      <td>515</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Wholesale dealer’s licence</td>
      <td>288</td>
      <td>317</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Wholesale dealer’s licence (reduced rate or   GSL) (4)</td>
      <td>172</td>
      <td>189</td>
    </tr>
    <tr>
      <td>19. Periodic fees for holding a   marketing authorisation</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>THMPD registration</td>
      <td>76</td>
      <td>84</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Licence Renewal Applications</td>
      <td>Manufacturers’ licences Non-orthodox   practitioner (NOP)</td>
      <td>178</td>
      <td>196</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>First renewal of a market authorisation   granted with a new active substance</td>
      <td>UKMA(GB) granted under the unfettered   access route</td>
      <td>747</td>
      <td>822</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>First renewal of a market authorisation   granted with a new active substance</td>
      <td>UKMA(GB) previously granted by EU   (automatic recognition)</td>
      <td>747</td>
      <td>822</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>First renewal of a market authorisation   granted with a new active substance</td>
      <td>All other cases</td>
      <td>9,682</td>
      <td>10,650</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Reclassification</td>
      <td>P to GSL - Additional fee for MA or PI   application with reclassification element from P to GSL (3), (4)</td>
      <td>8,162</td>
      <td>8,978</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Reclassification</td>
      <td>Reclassification variation application P to   GSL</td>
      <td>8,162</td>
      <td>8,978</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Reclassification</td>
      <td>Reclassification variation application (PI)   (analogous product)</td>
      <td>176</td>
      <td>194</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Assessment of labels and leaflets</td>
      <td>Single or first application (5)</td>
      <td>518</td>
      <td>570</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Assessment of labels and leaflets</td>
      <td>National (BROMI) - Article 61 (3)   Notification (6)</td>
      <td>186</td>
      <td>205</td>
    </tr>
    <tr>
      <td>20. Licence renewals,   reclassifications and assessment of labels and leaflets: fees</td>
      <td>&nbsp;</td>
      <td>Assessment of labels and leaflets</td>
      <td>Parallel imports</td>
      <td>328</td>
      <td>361</td>
    </tr>
    <tr>
      <td>21. Orphan Marketing Products: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Orphan Major (Full fee)</td>
      <td>92,753</td>
      <td>102,028</td>
    </tr>
    <tr>
      <td>21. Orphan Marketing Products: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Orphan Major (exceptional circumstances in   which point 6 pf Part II of Annex 1 in the 2001 Directive applies)</td>
      <td>29,732</td>
      <td>32,705</td>
    </tr>
    <tr>
      <td>21. Orphan Marketing Products: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Orphan Complex (Full Fee)</td>
      <td>25,643</td>
      <td>28,207</td>
    </tr>
    <tr>
      <td>21. Orphan Marketing Products: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Orphan Standard (Full Fee)</td>
      <td>9,402</td>
      <td>10,342</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Major Safety Review (1-2 active   ingredients)</td>
      <td>51,286</td>
      <td>56,415</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Major Safety Review (3 active   ingredients)</td>
      <td>59,595</td>
      <td>65,555</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Major Safety Review (4 active   ingredients)</td>
      <td>67,904</td>
      <td>74,694</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Major Safety Review (5 or more active ingredients)</td>
      <td>76,213</td>
      <td>83,834</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Periodic Safety Update Report (PSUR)   single assessment: Full Fee</td>
      <td>890</td>
      <td>979</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Periodic Safety Update Report (PSUR) single   assessment: Half Fee</td>
      <td>445</td>
      <td>490</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>PV Post Authorisation Safety Study (PASS)   protocol</td>
      <td>8,309</td>
      <td>9,140</td>
    </tr>
    <tr>
      <td>22. Pharmacovigilance (PV) Safety   Review: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Assessment of PASS Results</td>
      <td>8,309</td>
      <td>9,140</td>
    </tr>
    <tr>
      <td>23. Plasma Master File (PMF) &amp;   Vaccine Antigen Master File certification or certified annual update work:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Certification of new PMF (for scientific   &amp; technical evaluation)</td>
      <td>8,309</td>
      <td>9,140</td>
    </tr>
    <tr>
      <td>23. Plasma Master File (PMF) &amp;   Vaccine Antigen Master File certification or certified annual update work:   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Vaccine Antigen Master File (VAMF)   certification</td>
      <td>8,309</td>
      <td>9,140</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (NAS) -   Module 3 (chemical, pharmaceutical and biological information)</td>
      <td>23,188</td>
      <td>25,507</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (NAS) -   Module 4 (non-clinical reports)</td>
      <td>23,188</td>
      <td>25,507</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (NAS) -   Module 5 (clinical study reports)</td>
      <td>23,188</td>
      <td>25,507</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (Biosimilar)   - Module 3 (chemical, pharmaceutical and biological information)</td>
      <td>4,333</td>
      <td>4,766</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (Biosimilar)   - Module 4 (non-clinical reports)</td>
      <td>4,333</td>
      <td>4,766</td>
    </tr>
    <tr>
      <td>24. Pre-Assessment (Rolling Review):   fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Application by pre-assessment (Biosimilar)   - Module 5 (clinical study reports)</td>
      <td>4,333</td>
      <td>4,766</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Quality development only</td>
      <td>2,201</td>
      <td>2,421</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Safety development only</td>
      <td>2,201</td>
      <td>2,421</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Quality and safety development</td>
      <td>3,061</td>
      <td>3,367</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Clinical development only</td>
      <td>2,763</td>
      <td>3,039</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Quality and clinical development</td>
      <td>3,624</td>
      <td>3,986</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Safety and clinical development</td>
      <td>3,624</td>
      <td>3,986</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Quality, safety and clinical development</td>
      <td>4,487</td>
      <td>4,936</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Quality development only</td>
      <td>749</td>
      <td>824</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Safety development only</td>
      <td>749</td>
      <td>824</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Quality and safety development</td>
      <td>949</td>
      <td>1,044</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Clinical development only</td>
      <td>949</td>
      <td>1,044</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Quality and clinical development</td>
      <td>1,299</td>
      <td>1,429</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Safety and clinical development</td>
      <td>1,299</td>
      <td>1,429</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Quality, safety and clinical development</td>
      <td>1,648</td>
      <td>1,813</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pre-consultation application meetings on   devices incorporating an ancillary medicinal substance</td>
      <td>&nbsp;</td>
      <td>Broader scope meetings</td>
      <td>4,451</td>
      <td>4,896</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pharmacovigilance advice meetings</td>
      <td>&nbsp;</td>
      <td>Standard meeting</td>
      <td>3,061</td>
      <td>3,367</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pharmacovigilance advice meetings</td>
      <td>&nbsp;</td>
      <td>Major meeting</td>
      <td>3,624</td>
      <td>3,986</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pharmacovigilance advice meetings</td>
      <td>&nbsp;</td>
      <td>Post-authorisation regulatory advice   meetings</td>
      <td>2,763</td>
      <td>3,039</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pharmacovigilance advice meetings</td>
      <td>&nbsp;</td>
      <td>Advertising advice</td>
      <td>2,201</td>
      <td>2,421</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Pharmacovigilance advice meetings</td>
      <td>&nbsp;</td>
      <td>Advice on labels and leaflets</td>
      <td>2,201</td>
      <td>2,421</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Reclassification advice meetings</td>
      <td>&nbsp;</td>
      <td>Pharmacy to General Sales List switch</td>
      <td>2,763</td>
      <td>3,039</td>
    </tr>
    <tr>
      <td>26. Scientific advice meetings: fees</td>
      <td>Reclassification advice meetings</td>
      <td>&nbsp;</td>
      <td>Prescription Only Medicine to Pharmacy   switch</td>
      <td>3,624</td>
      <td>3,986</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require three or fewer   tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>180</td>
      <td>198</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require three or fewer   tests</td>
      <td>Fee payable where the licensing authority   carries out a paper-based assessment</td>
      <td>90</td>
      <td>99</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require four or five   tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>215</td>
      <td>237</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require four or five   tests</td>
      <td>Fee payable where the licensing authority carries   out a paper-based assessment</td>
      <td>90</td>
      <td>99</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require six or more   tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>230</td>
      <td>253</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Plasma pools which require six or more   tests</td>
      <td>Fee payable where the licensing authority   carries out a paper-based assessment</td>
      <td>90</td>
      <td>99</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band A – single component product, other   than Botulinum toxin. requiring five or fewer in vitro tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>1,660</td>
      <td>1,826</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band B – Factor VIII, Factor VIX or   intravenous Immunoglobin</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>1,910</td>
      <td>2,101</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band C – Multi-component product, or   Botulinum toxin, requiring five or fewer in vitro tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>2,340</td>
      <td>2,574</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band D – product requiring six to nine in   vitro tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>3,690</td>
      <td>4,059</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band E – product requiring (a) ten or more   in vitro tests, or (b) one or more in vivo tests</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>6,410</td>
      <td>7,051</td>
    </tr>
    <tr>
      <td>30. Testing of samples: fees</td>
      <td>&nbsp;</td>
      <td>Band F – one or more tests that must be   carried out under containment measures applicable to hazard Group 3 or 4   biological agents under Control of Substances Hazardous to Health Regulations   2002 (123) or requires use of human tissue cells as part of testing</td>
      <td>Fee payable where the licensing authority   carries out a full assessment</td>
      <td>10,350</td>
      <td>11,385</td>
    </tr>
    <tr>
      <td>34. Variations: licence variations   application fees</td>
      <td>&nbsp;</td>
      <td>Type II complex</td>
      <td>National</td>
      <td>8,309</td>
      <td>9,140</td>
    </tr>
    <tr>
      <td>34. Variations: licence variations   application fees</td>
      <td>&nbsp;</td>
      <td>Extended type II complex</td>
      <td>National</td>
      <td>25,643</td>
      <td>28,207</td>
    </tr>
    <tr>
      <td>34. Variations: licence variations   application fees</td>
      <td>&nbsp;</td>
      <td>Chapter II of Commission Regulation (EC)   /1234/2008 (as amended for CMS). In addition, variations submitted under the   relevant National reliance/recognition routes.</td>
      <td>Single kind variation - Type II Complex   Variation</td>
      <td>2,493</td>
      <td>2,742</td>
    </tr>
    <tr>
      <td>34. Variations: licence variations   application fees</td>
      <td>&nbsp;</td>
      <td>Chapter II of Commission Regulation (EC)   /1234/2008 (as amended for CMS). In addition, variations submitted under the   relevant National reliance/recognition routes.</td>
      <td>Single kind variation - Extended Type II   Complex Variation</td>
      <td>7,693</td>
      <td>8,462</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Minor variation (Type IB) group fee   (national)</td>
      <td>622</td>
      <td>684</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Major variation (Type II) group fee   (national)</td>
      <td>1,652</td>
      <td>1,817</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Major variation (Type II) complex group fee   (national)</td>
      <td>9,010</td>
      <td>9,911</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Major variation (Type II) extended complex   group fee (national)</td>
      <td>26,276</td>
      <td>28,904</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>Chapter II of Commission Regulation (EC)   /1234/2008 (as amended for CMS). In addition, variations submitted under the   relevant National reliance/recognition routes.</td>
      <td>Major Variation (Type II) Complex Group   Application</td>
      <td>2,703</td>
      <td>2,973</td>
    </tr>
    <tr>
      <td>35. Variations: licence variations   applications groups fees</td>
      <td>&nbsp;</td>
      <td>Chapter II of Commission Regulation (EC)   /1234/2008 (as amended for CMS). In addition, variations submitted under the relevant   National reliance/recognition routes.</td>
      <td>Major Variation (Type II) Extended Complex   Group Application</td>
      <td>7,883</td>
      <td>8,671</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Parallel import (PI)</td>
      <td>Standard</td>
      <td>357</td>
      <td>393</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Manufacturer’s licences (including   traditional herbal medicines)</td>
      <td>Standard</td>
      <td>514</td>
      <td>565</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Manufacturer’s licences (including   traditional herbal medicines)</td>
      <td>Administrative</td>
      <td>257</td>
      <td>283</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Wholesale dealers’ licences (includes Traditional   Herbal Medicinal Products)</td>
      <td>Standard</td>
      <td>486</td>
      <td>535</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Wholesale dealers’ licences (includes Traditional   Herbal Medicinal Products)</td>
      <td>Administrative</td>
      <td>257</td>
      <td>283</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Clinical trial authorisations</td>
      <td>Amendments to 1 part of dossier</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Clinical trial authorisations</td>
      <td>Amendments to 2 parts of dossier</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Clinical trial authorisations</td>
      <td>Amendments to 3 parts of dossier</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>36. Variations: other licence   variations applications fees</td>
      <td>&nbsp;</td>
      <td>Clinical trial authorisations</td>
      <td>Protocol</td>
      <td>225</td>
      <td>248</td>
    </tr>
    <tr>
      <td>38. Wholesale distribution   authorisations: fees</td>
      <td>&nbsp;</td>
      <td>New Applications</td>
      <td>Change of ownership</td>
      <td>399</td>
      <td>439</td>
    </tr>
    <tr>
      <td>38. Wholesale distribution   authorisations: fees</td>
      <td>&nbsp;</td>
      <td>New Applications</td>
      <td>Standard variation</td>
      <td>486</td>
      <td>535</td>
    </tr>
    <tr>
      <td>38. Wholesale distribution   authorisations: fees</td>
      <td>&nbsp;</td>
      <td>New Applications</td>
      <td>Administrative variation</td>
      <td>257</td>
      <td>283</td>
    </tr>
    <tr>
      <td>38. Wholesale distribution   authorisations: fees</td>
      <td>&nbsp;</td>
      <td>Inspections</td>
      <td>Issue of Good Distribution Practice   Certificates</td>
      <td>68</td>
      <td>75</td>
    </tr>
  </tbody>
</table>

<h2>Table 2 – Fees that increase above indexation to achieve cost-based recovery</h2>

<table>
  <thead>
    <tr>
      <th scope="col" style="text-align: center">Fee Name</th>
      <th scope="col" style="text-align: center">Current   Fee (£)</th>
      <th scope="col" style="text-align: center">Proposed   Fee (£)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align: center">Inspection - Full day rate (Good Manufacturing   Practice, Good Clinical Practice and Pharmacovigilance)</td>
      <td style="text-align: center">2,655</td>
      <td style="text-align: center">3,651</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Full day rate (Good Distribution   Practice)</td>
      <td style="text-align: center">1,936</td>
      <td style="text-align: center">2,662</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Full day rate (Blood banks and other   blood establishments)</td>
      <td style="text-align: center">2,583</td>
      <td style="text-align: center">3,552</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Half day rate (Good Manufacturing   Practice, Good Clinical Practice and Pharmacovigilance)</td>
      <td style="text-align: center">1,328</td>
      <td style="text-align: center">1,825</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Half day rate (Good Distribution   Practice)</td>
      <td style="text-align: center">968</td>
      <td style="text-align: center">1,331</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Half day rate (Blood banks and other   blood establishments)</td>
      <td style="text-align: center">1,292</td>
      <td style="text-align: center">1,776</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Office based evaluation and risk   assessments (Good Manufacturing Practice, Good Clinical Practice and   Pharmacovigilance)</td>
      <td style="text-align: center">1,863</td>
      <td style="text-align: center">2,562</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Office based risk assessments   (Wholesale distribution authorisations)</td>
      <td style="text-align: center">1,354</td>
      <td style="text-align: center">1,862</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection – Traditional Herbal Medicinal   Product/Homeopathic only (Wholesale distribution authorisations)</td>
      <td style="text-align: center">1,367</td>
      <td style="text-align: center">1,880</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - reduced rate Traditional Herbal   Medicinal Product/Homeopathic only (Wholesale distribution authorisations)</td>
      <td style="text-align: center">744</td>
      <td style="text-align: center">1,023</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Standard application plus full   inspection fee (Wholesale distribution authorisations)</td>
      <td style="text-align: center">3,739</td>
      <td style="text-align: center">4,645</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Reduced application plus full   inspection fee (Wholesale distribution authorisations)</td>
      <td style="text-align: center">2,838</td>
      <td style="text-align: center">3,654</td>
    </tr>
    <tr>
      <td style="text-align: center">Inspection - Reduced application plus reduced   Inspection fee - General Sales List (GSL) only (Wholesale distribution   authorisations)</td>
      <td style="text-align: center">1,870</td>
      <td style="text-align: center">2,323</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Extended application group (National   fee)</td>
      <td style="text-align: center">25,643</td>
      <td style="text-align: center">33,003</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Single kind variation - Type IB (Falling   under scope of Chapter II Commission Regulation 1234/2008)</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Single kind variation - Type II (Falling   under scope of Chapter II Commission Regulation 1234/2008)</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Type IB National</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Reclassification Type IB</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Minor Variation (Type IB) Group   Application (Falling under scope of Chapter II Commission Regulation   1234/2008)</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Certified Annual Update of a Plasma Master File   (PMF)</td>
      <td style="text-align: center">277</td>
      <td style="text-align: center">344</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Major (Type II) Group Application   (Falling under scope of Chapter II Commission Regulation 1234/2008)</td>
      <td style="text-align: center">496</td>
      <td style="text-align: center">1,255</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Type II Standard National</td>
      <td style="text-align: center">734</td>
      <td style="text-align: center">1,308</td>
    </tr>
    <tr>
      <td style="text-align: center">Variation - Reclassification variation application   (MA) (analogous product)</td>
      <td style="text-align: center">734</td>
      <td style="text-align: center">1,308</td>
    </tr>
    <tr>
      <td style="text-align: center">Certified Annual Update of a Plasma Master File   (PMF) - significant changes to safety information</td>
      <td style="text-align: center">734</td>
      <td style="text-align: center">1,308</td>
    </tr>
    <tr>
      <td style="text-align: center">Parallel   imports fees - standard application</td>
      <td style="text-align: center">6,663</td>
      <td style="text-align: center">8,722</td>
    </tr>
    <tr>
      <td style="text-align: center">Reclassification – Prescription Only Medicine to   Pharmacy (Additional for MA or PI application)</td>
      <td style="text-align: center">11,992</td>
      <td style="text-align: center">33,003</td>
    </tr>
    <tr>
      <td style="text-align: center">Reclassification – Prescription Only Medicine to   Pharmacy (variation application)</td>
      <td style="text-align: center">11,992</td>
      <td style="text-align: center">33,003</td>
    </tr>
    <tr>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td style="text-align: center">Safety   and quality vetting of unlicensed imported medicines fees:</td>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 1 - 20</td>
      <td style="text-align: center">130</td>
      <td style="text-align: center">70</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 21 - 100</td>
      <td style="text-align: center">519</td>
      <td style="text-align: center">350</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 101 - 1,000</td>
      <td style="text-align: center">2,077</td>
      <td style="text-align: center">2,400</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 1,001 - 5,000</td>
      <td style="text-align: center">10,383</td>
      <td style="text-align: center">12,000</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 5,001 - 20,000</td>
      <td style="text-align: center">25,957</td>
      <td style="text-align: center">30,000</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 20,001 - 50,000</td>
      <td style="text-align: center">51,914</td>
      <td style="text-align: center">60,000</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 50,001 - 100,000</td>
      <td style="text-align: center">103,828</td>
      <td style="text-align: center">120,000</td>
    </tr>
    <tr>
      <td style="text-align: center">Number of annual notifications: 100,001 +</td>
      <td style="text-align: center">155,742</td>
      <td style="text-align: center">200,000</td>
    </tr>
    <tr>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td style="text-align: center">Band A – single component product, other than   Botulinum toxin. requiring five or fewer in vitro tests</td>
      <td style="text-align: center">305</td>
      <td style="text-align: center">367</td>
    </tr>
    <tr>
      <td style="text-align: center">Band B – Factor VIII, Factor VIX or intravenous   Immunoglobin</td>
      <td style="text-align: center">305</td>
      <td style="text-align: center">367</td>
    </tr>
    <tr>
      <td style="text-align: center">Band C – Multi-component product, or Botulinum   toxin, requiring five or fewer in vitro tests</td>
      <td style="text-align: center">305</td>
      <td style="text-align: center">992</td>
    </tr>
    <tr>
      <td style="text-align: center">Band D – product requiring six to nine in vitro   tests</td>
      <td style="text-align: center">677</td>
      <td style="text-align: center">992</td>
    </tr>
    <tr>
      <td style="text-align: center">Band E – product requiring (a) ten or more in vitro   tests, or (b) one or more in vivo tests</td>
      <td style="text-align: center">677</td>
      <td style="text-align: center">1,849</td>
    </tr>
    <tr>
      <td style="text-align: center">Band F – one or more tests that must be carried out   under containment measures applicable to hazard Group 3 or 4 biological   agents under Control of Substances Hazardous to Health Regulations 2002 (123)   or requires use of human tissues or cells as part of testing</td>
      <td style="text-align: center">677</td>
      <td style="text-align: center">1,849</td>
    </tr>
    <tr>
      <td style="text-align: center">Initial   application for designation (covers both Approved Body and Notified Body)</td>
      <td style="text-align: center">8,252</td>
      <td style="text-align: center">35,672</td>
    </tr>
    <tr>
      <td style="text-align: center">Re-application to address ground for rejection of a   previous application</td>
      <td style="text-align: center">2,063</td>
      <td style="text-align: center">8,918</td>
    </tr>
    <tr>
      <td style="text-align: center">Initial designation audit</td>
      <td style="text-align: center">15,904</td>
      <td style="text-align: center">58,341</td>
    </tr>
    <tr>
      <td style="text-align: center">Surveillance</td>
      <td style="text-align: center">10,160</td>
      <td style="text-align: center">45,675</td>
    </tr>
    <tr>
      <td style="text-align: center">Witnessed Audit</td>
      <td style="text-align: center">4,404</td>
      <td style="text-align: center">10,072</td>
    </tr>
    <tr>
      <td style="text-align: center">Re-designation application fee</td>
      <td style="text-align: center">8,252</td>
      <td style="text-align: center">35,672</td>
    </tr>
    <tr>
      <td style="text-align: center">Re-designation audit</td>
      <td style="text-align: center">15,904</td>
      <td style="text-align: center">58,341</td>
    </tr>
    <tr>
      <td style="text-align: center">Follow up Audit - Major Closure</td>
      <td style="text-align: center">3,876</td>
      <td style="text-align: center">22,789</td>
    </tr>
    <tr>
      <td style="text-align: center">Follow up Audit - Special Clinical</td>
      <td style="text-align: center">2,586</td>
      <td style="text-align: center">18,583</td>
    </tr>
    <tr>
      <td style="text-align: center">Follow   up Audit - Process Specific</td>
      <td style="text-align: center">3,876</td>
      <td style="text-align: center">22,789</td>
    </tr>
    <tr>
      <td style="text-align: center">TSE Applications UK Conformity Assessment Bodies</td>
      <td style="text-align: center">532</td>
      <td style="text-align: center">1,297</td>
    </tr>
    <tr>
      <td style="text-align: center">In addition to each of the above, the below two fees   are for time spent on audit and travel:</td>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td style="text-align: center">Half day rate for auditing</td>
      <td style="text-align: center">361</td>
      <td style="text-align: center">631</td>
    </tr>
    <tr>
      <td style="text-align: center">Hourly rate for travel</td>
      <td style="text-align: center">90</td>
      <td style="text-align: center">171</td>
    </tr>
    <tr>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td style="text-align: center">Class I, IIa, or IIb other than implantable or   long-term invasive devices: Notification</td>
      <td style="text-align: center">3,820</td>
      <td style="text-align: center">7,472</td>
    </tr>
    <tr>
      <td style="text-align: center">Class I, IIa, or IIb other than implantable or   long-term invasive devices: Notification - re-notification in the event of an   objection</td>
      <td style="text-align: center">2,920</td>
      <td style="text-align: center">5,711</td>
    </tr>
    <tr>
      <td style="text-align: center">Class IIb implantable or long-term invasive, Class   III, and active implantable devices: Notification</td>
      <td style="text-align: center">5,040</td>
      <td style="text-align: center">15,627</td>
    </tr>
    <tr>
      <td style="text-align: center">Class IIb implantable or long-term invasive, Class   III, and active implantable devices: Notification - re-notification in the   event of an objection</td>
      <td style="text-align: center">3,570</td>
      <td style="text-align: center">11,069</td>
    </tr>
    <tr>
      <td style="text-align: center">Devices Registration</td>
      <td style="text-align: center">100</td>
      <td style="text-align: center">240</td>
    </tr>
    <tr>
      <td style="text-align: center">Devices Registration amendment</td>
      <td style="text-align: center">100</td>
      <td style="text-align: center">240</td>
    </tr>
    <tr>
      <td style="text-align: center">Devices Blood bank annual fee</td>
      <td style="text-align: center">492</td>
      <td style="text-align: center">967</td>
    </tr>
  </tbody>
</table>

<h2>Table 3 – New Fees</h2>

<table>
  <thead>
    <tr>
      <th scope="col">Fee Name</th>
      <th scope="col">Proposed Fee (£)</th>
      <td></td>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Conformity Assessment   Body Designation Applications – Extension to scope, new UKCA codes or Annex   (covers both Approved Body and Notified Body)</td>
      <td>18,212</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Conformity Assessment   Body Designation Applications – Extension to scope, where codes are limited   (covers both Approved Body and Notified Body)</td>
      <td>12,571</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Conformity Assessment   Body Audits – Subsidiary audit subject to additional fees   calculated by hourly rate and travel rates (covers both Approved Body and Notified Body)</td>
      <td>22,789</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Clinical investigations consultation fee   (optional) – Device Regulatory Advice meeting</td>
      <td>906</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Clinical Investigations consultation fee   optional service – Clinical Investigations statistical review</td>
      <td>782</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>In Vitro Diagnostic (IVD) Performance Report (also known as IVD performance evaluation   report)</td>
      <td>7,472</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Scientific Advice - aligned to the Innovative   Licensing and Access Pathway (ILAP) Innovation Passport</td>
      <td>9,895</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Scientific Advice - aligned to the ILAP Target   Development Profile</td>
      <td>23,948</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Early Access to Medicines Scheme (EAMS) – Promising   Innovative Medicine (PIM) designation</td>
      <td>3,986</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>EAMS - fee for the assessment of the   scientific opinion for new chemical or biological medicinal products</td>
      <td>25,643</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>EAMS renewal fee for new chemical or   biological medicinal products (if applicable)</td>
      <td>12,821</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>EAMS - fee for the assessment of the   scientific opinion for new indications</td>
      <td>8,309</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>EAMS renewal fee for new indications (if   applicable)</td>
      <td>4,154</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Safety and quality   vetting of unlicensed imported medicines fees:</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 1-5</td>
      <td>100</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 6-10</td>
      <td>200</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 11-20</td>
      <td>400</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 21-50</td>
      <td>1,000</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 51-100</td>
      <td>2,000</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: 101-200</td>
      <td>4,000</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Number of annual product codes: per   additional 100 product codes above 200</td>
      <td>2,000</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Clinical Trials - Assessment of annual   safety reports</td>
      <td>248</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>Clinical Trials - Complex amendments</td>
      <td>1,800</td>
      <td>&nbsp;</td>
    </tr>
  </tbody>
</table>
</div>


</div>
</div>
    </div>
  </div>

  <div class="govuk-grid-row">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Back to top
</a>

  </div>
</div>

    </main>